Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 21–22

HOS-116415 · Präparat HOS-094447

21  Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of 10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and boosted ║ based on published data with PREZISTA is required, it is darunavir/ritonavir recommended to start with the lowest possible dose of rosuvastatin AUC ↑ 93%§ rosuvastatin and titrate up to the rosuvastatin Cmax ↑ 277%§ desired clinical effect while rosuvastatin Cmin ND§ monitoring for safety. § with darunavir/cobicistat 800/150 mg OTHER LIPID MODIFYING AGENTS Lomitapide Based on theoretical considerations Co-administration is boosted PREZISTA is expected to contraindicated (see section 4.3). increase the exposure of lomitapide when co-administered. (CYP3A inhibition) H2-RECEPTOR ANTAGONISTS Ranitidine # Boosted PREZISTA can be darunavir AUC ↔ 150 mg twice daily # darunavir Cmin ↔ co-administered with H2-receptor # darunavir Cmax ↔ antagonists without dose adjustments. IMMUNOSUPPRESSANTS Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the Sirolimus immunosuppressants will be increased immunosuppressive agent must be Tacrolimus when co-administered with boosted done when co-administration PREZISTA. occurs. (CYP3A inhibition) Everolimus Concomitant use of everolimus and boosted PREZISTA is not recommended. INHALED BETA AGONISTS Salmeterol Not studied. Concomitant use of Concomitant use of salmeterol and salmeterol and boosted darunavir may boosted PREZISTA is not increase plasma concentrations of recommended. The combination salmeterol. may result in increased risk of cardiovascular adverse event with salmeterol, including QT prolongation, palpitations and sinus tachycardia. NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with boosted once daily PREZISTA. However, adjustment PREZISTA/cobicistat may, in contrast, of the methadone dose may be increase methadone plasma necessary when concomitantly concentrations (see cobicistat SmPC). administered for a longer period of time. Therefore, clinical monitoring is recommended, as maintenance therapy may need to be adjusted in some patients. Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the 8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has norbuprenorphine AUC ↑ 46% not been established. Dose norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may norbuprenorphine Cmax ↑ 36% not be necessary when naloxone AUC ↔ co-administered with boosted PREZISTA but a careful clinical naloxone Cmin ND monitoring for signs of opiate naloxone Cmax ↔ toxicity is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lomitapide (HOS-086160) cobicistat (HOS-088111) rosuvastatin (HOS-086307) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) ritonavir (HOS-084521)